Mesenchymal Stem Cells Remain Host-Derived Independent of the Source of the Stem-Cell Graft and Conditioning Regimen Used

被引:51
作者
Bartsch, Kristina [1 ]
Al-Ali, Haifa [1 ]
Reinhardt, Annette [1 ]
Franke, Christina [1 ]
Hudecek, Michael [1 ]
Kamprad, Manja [2 ]
Tschiedel, Sabine [1 ]
Cross, Michael [1 ]
Niederwieser, Dietger [1 ]
Gentilini, Chiara [1 ]
机构
[1] Univ Leipzig, Dept Hematol & Oncol, D-4103 Leipzig, Germany
[2] Univ Leipzig, Div Immunol, D-4103 Leipzig, Germany
关键词
Mesenchymal stem cells; Allogeneic stem-cell transplantation; FISH; BONE-MARROW; PERIPHERAL-BLOOD; CORD BLOOD; ORIGIN; DIFFERENTIATION; TRANSPLANTATION;
D O I
10.1097/TP.0b013e3181938998
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Human bone marrow contains hematopoietic stern cells and stroma cells known as mesenchymal stern cells (MSC). MSC are cells with the morphological features of fibroblasts, which, in addition to their nursing function for hematopoietic stem cells, retain the ability to differentiate into cartilage, bone, fat, muscle, and tendon and have an important immunmodulatory function. To understand in more detail hematopoietic engraftment and immune modulation after hematopoietic cell transplantation, we investigated the ability of donor MSC to engraft after hematopoietic cell transplantation in dependency to the conditioning regimen (myeloablative vs. reduced intensity) and source of the graft (bone marrow vs. peripheral blood). Methods. Bone marrow MSC of 12 patients were analyzed, a median of 23.4 (range 0.9-137.8) months after human leukocyte antigen matched but gender mismatched bone marrow transplantation after myeloablative conditioning (n=4) or peripheral blood cell transplantation after myeloablative (n=4) or reduced intensity conditioning (n=4). MSC were characterized by morphology, positivity for CD 105(+), CD73(+), CD 44(+), and CID 90(+), and by their capacity to differentiate into adipocytic and osteogenic cells. Recipient and donor origins were determined by fluorescent in situ hybridization for sex chromosomes. Results. While overall blood and boric marrow chimerism was 100% donor type, MSC remained in all patients of recipient origin (>96%). There was no difference between patients receiving bone marrow and peripheral blood grafts, nor was any difference observed between patients receiving full intensity in comparison with reduced intensity conditioning. Conclusions. We conclude that MSC remain of host type irrespective of the conditioning regimen and graft Source.
引用
收藏
页码:217 / 221
页数:5
相关论文
共 15 条
  • [1] Origin and differentiation of human and murine stroma
    Dennis, JE
    Charbord, P
    [J]. STEM CELLS, 2002, 20 (03) : 205 - 214
  • [2] Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli
    Di Nicola, M
    Carlo-Stella, C
    Magni, M
    Milanesi, M
    Longoni, PD
    Matteucci, P
    Grisanti, S
    Gianni, AM
    [J]. BLOOD, 2002, 99 (10) : 3838 - 3843
  • [3] Mesenchymal stem cells obtained after bone marrow transplantation or peripheral blood stem cell transplantation originate from host tissue
    Dickhut, A
    Schwerdtfeger, R
    Kuklick, L
    Ritter, M
    Thiede, C
    Neubauer, A
    Brendel, C
    [J]. ANNALS OF HEMATOLOGY, 2005, 84 (11) : 722 - 727
  • [4] Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone
    Horwitz, EM
    Gordon, PL
    Koo, WKK
    Marx, JC
    Neel, MD
    McNall, RY
    Muul, L
    Hofmann, T
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (13) : 8932 - 8937
  • [5] Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy
    Koç, ON
    Gerson, SL
    Cooper, BW
    Dyhouse, SM
    Haynesworth, SE
    Caplan, AI
    Lazarus, HM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (02) : 307 - 316
  • [6] A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential
    Kögler, G
    Sensken, S
    Airey, JA
    Trapp, T
    Müschen, M
    Feldhahn, N
    Liedtke, S
    Sorg, RV
    Fischer, J
    Rosenbaum, C
    Greschat, S
    Knipper, A
    Bender, J
    Degistirici, O
    Gao, JZ
    Caplan, AI
    Colletti, E
    Almeida-Porada, G
    Müller, HW
    Zanjani, E
    Wernet, P
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 200 (02) : 123 - 135
  • [7] Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells
    Le Blanc, K
    Rasmusson, I
    Sundberg, B
    Götherström, C
    Hassan, M
    Uzunel, M
    Ringdén, O
    [J]. LANCET, 2004, 363 (9419) : 1439 - 1441
  • [8] Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype
    Lee, ST
    Jang, JH
    Cheong, JW
    Kim, JS
    Maemg, HY
    Hahn, JS
    Ko, YW
    Min, YH
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2002, 118 (04) : 1128 - 1131
  • [9] Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MNF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases
    Niederwieser, D
    Maris, M
    Shizuru, JA
    Petersdorf, E
    Hegenbart, U
    Sandmaier, BM
    Maloney, DG
    Storer, B
    Lange, T
    Chauncey, T
    Deininger, M
    Pönisch, W
    Anasetti, C
    Woolfrey, A
    Little, MT
    Blume, KG
    McSweeney, PA
    Storb, RF
    [J]. BLOOD, 2003, 101 (04) : 1620 - 1629
  • [10] OWEN M, 1988, CIBA F SYMP, V136, P42